Moreover, Miladinović et al. compared the results of Her2 expression in lung adenocarcinoma samples using two different antibodies, the HercepTest Dako and PATHWAY anti-HER2 (4B5) and they reported a lower rate of positivity using the 4B5 antibody (the one we used in this study), 2.7% vs. 6.4%. This evidence concerns the gene ERBB2 and lung adenocarcinoma.